Shares of this biotech giant have lost 19.2% in the past six months against the industry’s growth of 0.6%. The stock has also ...

LB Pharmaceuticals, which has a schizophrenia medicine headed for late-stage testing, broke one of the longest droughts for ...

PGIM shares how the Jennison Health Sciences Fund weathered Q2 volatility by leaning into undervalued innovators. Discover ...

In September 2025, The FDA approved an injectable extended-release risperidone suspension from Amneal Pharmaceuticals, ...

Detailed price information for Puretech Health Plc ADR (PRTC-Q) from The Globe and Mail including charting and trades.